Search

Your search keyword '"Maastricht University [Maastricht]-Maastricht University [Maastricht]"' showing total 20 results
Start Over Author "Maastricht University [Maastricht]-Maastricht University [Maastricht]" Topic business.industry
20 results on '"Maastricht University [Maastricht]-Maastricht University [Maastricht]"'

1. OBEDIS Core Variables Project: European Expert Guidelines on a Minimal Core Set of Variables to Include in Randomized, Controlled Clinical Trials of Obesity Interventions

Author

António L. Palmeira, Thorkild I. A. Sørensen, Martin Neovius, Martine Laville, Mikael Rydén, Andrea Natali, Maud Alligier, Romain Barrès, Kristina Campbell, David Jacobi, I. Sadaf Farooqi, Jean-Michel Oppert, Helen M. Roche, André Scheen, Karine Clément, Ellen E. Blaak, Yves Boirie, Gijs H. Goossens, Jason C.G. Halford, Luc Tappy, Nathalie Farpour-Lambert, Hannele Yki-Järvinen, Uberto Pagotto, Chantal Simon, Jörg Hager, Jildau Bouwman, Paul Brunault, Gema Frühbeck, Dominique Langin, Olivier Ziegler, Chantal Julia, Hans Hauner, Centre de Recherche en Nutrition Humaine Rhône-Alpes (CRNH-RA), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-CHU Grenoble-Hospices Civils de Lyon (HCL)-CHU Saint-Etienne-Université Jean Monnet [Saint-Étienne] (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE)-Université Grenoble Alpes (UGA), University of Copenhagen = Københavns Universitet (KU), Novo Nordisk Foundation Center for Basic Metabolic Research (CBMR), Faculty of Health and Medical Sciences, University of Copenhagen = Københavns Universitet (KU)-University of Copenhagen = Københavns Universitet (KU), Maastricht University Medical Centre (MUMC), Maastricht University [Maastricht], CHU Clermont-Ferrand, Netherlands Organization for Applied Scientific Research (TNO), TNO Science and Industry, Institut National de la Santé et de la Recherche Médicale (INSERM), Université de Tours (UT), Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), Imagerie et cerveau (iBrain - Inserm U1253 - UNIV Tours ), Université de Tours (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM), KC Microbiome Communications Group, Nutrition et obésités: approches systémiques (nutriomics) (UMR-S 1269 INSERM - Sorbonne Université), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), NIHR Biomedical Research Centre [London], Guy's and St Thomas' NHS Foundation Trust-King‘s College London, University of Cambridge [UK] (CAM), Université de Genève (UNIGE), Geneva University Hospitals and Geneva University, Clínica Universidad de Navarra [Pamplona], Nestlé Institute of Health Sciences SA [Lausanne, Switzerland], University of Liverpool, Technische Universität Munchen - Université Technique de Munich [Munich, Allemagne] (TUM), Klinikums rechts der Isar, Centre National de la Recherche Scientifique (CNRS), Université de Nantes (UN), unité de recherche de l'institut du thorax UMR1087 UMR6291 (ITX), Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Equipe 3: EREN- Equipe de Recherche en Epidémiologie Nutritionnelle (CRESS - U1153), Université Sorbonne Paris Nord-Centre de Recherche Épidémiologie et Statistique Sorbonne Paris Cité (CRESS (U1153 / UMR_A_1125 / UMR_S_1153)), Conservatoire National des Arts et Métiers [CNAM] (CNAM)-Université Sorbonne Paris Cité (USPC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Paris (UP)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE)-Conservatoire National des Arts et Métiers [CNAM] (CNAM)-Université Sorbonne Paris Cité (USPC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Paris (UP)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées, Institut des Maladies Métaboliques et Cardiovasculaires (I2MC), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM), University of Pisa - Università di Pisa, Karolinska Institutet [Stockholm], CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Unité de Recherche sur les Maladies Cardiovasculaires, du Métabolisme et de la Nutrition = Institute of cardiometabolism and nutrition (ICAN), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU), Alma Mater Studiorum University of Bologna (UNIBO), Université de Lisbonne, University College Dublin [Dublin] (UCD), Centre Hospitalier Universitaire de Liège (CHU-Liège), Cardiovasculaire, métabolisme, diabétologie et nutrition (CarMeN), Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National des Sciences Appliquées de Lyon (INSA Lyon), Institut National des Sciences Appliquées (INSA)-Université de Lyon-Institut National des Sciences Appliquées (INSA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Hospices Civils de Lyon (HCL), Université de Lausanne (UNIL), Minerva Foundation Institute for Medical Research, University of Helsinki, Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Joint Programming Initiative Heathy Diet for Healthy Life, Alligier M., Barres R., Blaak E.E., Boirie Y., Bouwman J., Brunault P., Campbell K., Clement K., Farooqi I.S., Farpour-Lambert N.J., Fruhbeck G., Goossens G.H., Hager J., Halford J.C.G., Hauner H., Jacobi D., Julia C., Langin D., Natali A., Neovius M., Oppert J.M., Pagotto U., Palmeira A.L., Roche H., Ryden M., Scheen A.J., Simon C., Sorensen T.I.A., Tappy L., Yki-Jarvinen H., Ziegler O., Laville M., FCRIN/FORCE Network, Centre de Recherche en Nutrition Humaine Rhône-Alpes, Novo Nordisk, Department of Human Biology, Maastricht University Medical Center (MUMC), Unité de Nutrition Humaine - Clermont Auvergne (UNH), Institut National de la Recherche Agronomique (INRA)-Université Clermont Auvergne (UCA), Nutrition clinique, Centre Hospitalier Universitaire Gabriel Montpied, TNO,Netherlands Organisation for Applied Scientific Research, UMR U 1253, Université de Tours, Nutrition et obésité : approches systémiques, Sorbonne Université, Wellcome-MRC Institute of Metabolic Science and NIHR Biomedical Research Centre, University of Cambridge, Service of Therapeutic Education for Chronic Diseases, Department of Community Health, Primary Care and Emergency, Geneva University Hospitals, Department of Endocrinology and Nutrition, Navarra Public Health Institute, Centro de Investigación Biomédica en Red de la Fisiopatología de la Obesidad y Nutrición - Biomedical Research Center in Red-Physiopathology of Obesity and Nutrition (CIBEROBN), University of Navarra, University of Cape Town, Metabolic Phenotyping, Nestlé Institute of Health Sciences, Psychological Sciences, University of Liverpool (University of Liverpool), Institut für Ernährungsmedizin des Klinikums Rechts der Isar, Technical University of Munich (TUM), Institut du Thorax, Centre Hospitalier Universitaire de Nantes, Centre de Recherche Épidémiologie et Statistique Sorbonne Paris Cité (CRESS (U1153 / UMR_A_1125 / UMR_S_1153)), Université Paris Diderot - Paris 7 (UPD7)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de la Recherche Agronomique (INRA)-Université Paris Descartes - Paris 5 (UPD5)-Université Sorbonne Paris Cité (USPC), Université Toulouse III - Paul Sabatier, Centre Hospitalier Universitaire de Toulouse, Department of Clinical and Experimental Medicine, Università degli studi di Napoli Federico II, Department of Medicine (Solna), Nutrition, Institut de Cardiométabolisme et Nutrition (ICAN), CHU Pitié-Salpêtrière [APHP], Department of Medical and Surgical Sciences, Universita degli Studi di Padova, CIPER, PANO-SR, Faculty of Human Kinetics, University of Lisbon, UCD Institute of Food and Health, University College Dublin (UCD), Department of Medicine, The University of Sydney, Diabètes, Nutrition et maladies métaboliques, Institut National de la Recherche Agronomique (INRA)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Hospices Civils de Lyon (HCL), Physiologie, Université de Picardie Jules Verne (UPJV), Helsinki University Central Hospital, Endocrinologie, Diabetes et Nutrition, Hôpital Brabois, Maastricht University [Maastricht]-Maastricht University [Maastricht], Unité de Nutrition Humaine (UNH), Institut National de la Recherche Agronomique (INRA)-Université Clermont Auvergne [2017-2020] (UCA [2017-2020]), Conservatoire National des Arts et Métiers [CNAM] (CNAM)-Université Sorbonne Paris Cité (USPC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Paris (UP)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Sorbonne Université-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Institut National des Sciences Appliquées (INSA)-Université de Lyon-Institut National des Sciences Appliquées (INSA)-Hospices Civils de Lyon (HCL)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut National de la Recherche Agronomique (INRA)-Université Paris Diderot - Paris 7 (UPD7)-Université Paris Descartes - Paris 5 (UPD5)-Université Sorbonne Paris Cité (USPC)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre Hospitalier Régional Universitaire de Tours (CHRU TOURS), Université de Tours-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées, ProdInra, Archive Ouverte, Université de Lyon-Université de Lyon-CHU Grenoble-Hospices Civils de Lyon (HCL)-CHU Saint-Etienne-Université Jean Monnet - Saint-Étienne (UJM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE)-Université Grenoble Alpes (UGA), University of Copenhagen = Københavns Universitet (UCPH), University of Copenhagen = Københavns Universitet (UCPH)-University of Copenhagen = Københavns Universitet (UCPH), Nutrition et obésités: approches systémiques (UMR-S 1269) (Nutriomics), Université de Genève = University of Geneva (UNIGE), Unité de recherche de l'institut du thorax (ITX-lab), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN), Conservatoire National des Arts et Métiers [CNAM] (CNAM), HESAM Université - Communauté d'universités et d'établissements Hautes écoles Sorbonne Arts et métiers université (HESAM)-HESAM Université - Communauté d'universités et d'établissements Hautes écoles Sorbonne Arts et métiers université (HESAM)-Université Sorbonne Paris Cité (USPC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE)-Conservatoire National des Arts et Métiers [CNAM] (CNAM), HESAM Université - Communauté d'universités et d'établissements Hautes écoles Sorbonne Arts et métiers université (HESAM)-HESAM Université - Communauté d'universités et d'établissements Hautes écoles Sorbonne Arts et métiers université (HESAM)-Université Sorbonne Paris Cité (USPC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Unité de Recherche sur les Maladies Cardiovasculaires, du Métabolisme et de la Nutrition = Research Unit on Cardiovascular and Metabolic Diseases (ICAN), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Institut de Cardiométabolisme et Nutrition = Institute of Cardiometabolism and Nutrition [CHU Pitié Salpêtrière] (IHU ICAN), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-CHU Pitié-Salpêtrière [AP-HP], Université de Lyon-Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Hospices Civils de Lyon (HCL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Université de Lausanne = University of Lausanne (UNIL), Helsingin yliopisto = Helsingfors universitet = University of Helsinki, HUS Internal Medicine and Rehabilitation, Humane Biologie, and RS: NUTRIM - R1 - Obesity, diabetes and cardiovascular health

Subjects
0301 basic medicine, Research design, Gerontology, Health (social science), Psychological intervention, Choice Behavior, 0302 clinical medicine, QUALITY-OF-LIFE, OBSTRUCTIVE SLEEP-APNEA, Medicine, Medical History Taking, lcsh:RC620-627, Interventions, METABOLIC SYNDROME, Randomized Controlled Trials as Topic, ddc:616, [SDV.MHEP] Life Sciences [q-bio]/Human health and pathology, Precision medicine, Prognosis, C-REACTIVE PROTEIN, 3. Good health, Europe, lcsh:Nutritional diseases. Deficiency diseases, CARDIOVASCULAR-DISEASE, Research Design, Variable, lcsh:Nutrition. Foods and food supply, Human, Prognosi, education, WEIGHT-LOSS, lcsh:TX341-641, Intervention, 030209 endocrinology & metabolism, GASTRIC BYPASS-SURGERY, Guidelines, Patient care, 03 medical and health sciences, Variables, Physiology (medical), Humans, CORONARY-HEART-DISEASE, Obesity, Expert Testimony, Core set, 030109 nutrition & dietetics, business.industry, Stratification, medicine.disease, Diet, BODY-MASS INDEX, Clinical trial, PHYSICAL-ACTIVITY, Biological Variation, Population, 3121 General medicine, internal medicine and other clinical medicine, Metabolic syndrome, business, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
Abstract

Heterogeneity of interindividual and intraindividual responses to interventions is often observed in randomized, controlled trials for obesity. To address the global epidemic of obesity and move toward more personalized treatment regimens, the global research community must come together to identify factors that may drive these heterogeneous responses to interventions. This project, called OBEDIS (OBEsity Diverse Interventions Sharing - focusing on dietary and other interventions), provides a set of European guidelines for a minimal set of variables to include in future clinical trials on obesity, regardless of the specific endpoints. Broad adoption of these guidelines will enable researchers to harmonize and merge data from multiple intervention studies, allowing stratification of patients according to precise phenotyping criteria which are measured using standardized methods. In this way, studies across Europe may be pooled for better prediction of individuals' responses to an intervention for obesity - ultimately leading to better patient care and improved obesity outcomes. © 2020 The Author(s) Published by S. Karger AG, Basel.

Published
2020

2. Innovative devices for actinic keratoses: a hot‐button issue

Author

Nicole W.J. Kelleners-Smeets, Mahtab Samimi, Service de dermatologie (CHRU de Tours), Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), Infectiologie et Santé Publique (UMR ISP), Université de Tours (UT)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Service de dermatologie (Maastricht), Maastricht University Medical Centre (MUMC), Maastricht University [Maastricht]-Maastricht University [Maastricht], RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy, Dermatologie, MUMC+: MA Dermatologie (9), Centre Hospitalier Régional Universitaire de Tours (CHRU TOURS), and Université de Tours-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE)

Subjects
medicine.medical_specialty, Keratosis, business.industry, [SDV]Life Sciences [q-bio], Dermatology, Actinic keratoses, medicine.disease, 030207 dermatology & venereal diseases, 03 medical and health sciences, 0302 clinical medicine, 030220 oncology & carcinogenesis, medicine, business, ComputingMilieux_MISCELLANEOUS, [SDV.MHEP.DERM]Life Sciences [q-bio]/Human health and pathology/Dermatology
Abstract

International audience

Published
2020

3. 2018 Joint European consensus document on the management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous cardiovascular interventions:a joint consensus document of the European Heart Rhythm Association (EHRA), European Society of Cardiology Working Group on Thrombosis, European Association of Percutaneous Cardiovascular Interventions (EAPCI), and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS), Latin America Heart Rhythm Society (LAHRS), and Cardiac Arrhythmia Society of Southern Africa (CASSA)

Author

Fauchier, Laurent, Cinaud, Alexandre, Brigadeau, François, Lepillier, Antoine, Pierre, Bertrand, Abbey, Selim, Fatemi, Marjaneh, Franceschi, Frederic, Guedeney, Paul, Jacon, Peggy, Paziaud, Olivier, Venier, Sandrine, Deharo, Jean Claude, Gras, Daniel, Klug, Didier, Mansourati, Jacques, Montalescot, Gilles, Piot, Olivier, Defaye, Pascal, Lip, Gregory, Collet, Jean-Phillippe, Haude, Michael, Byrne, Robert, Chung, Eugene, Halvorsen, Sigrun, Lau, Dennis, Lopez-Cabanillas, Nestor, Lettino, Maddalena, Marin, Francisco, Obel, Israel, Rubboli, Andrea, Storey, Robert, Valgimigli, Marco, Huber, Kurt, Potpara, Tatjana, Blomström Lundqvist, Carina, Crijns, Harry, Steffel, Jan, Heidbüchel, Hein, Stankovic, Goran, Airaksinen, Juhani, ten Berg, Jurrien, Capodanno, Davide, James, Stefan, Bueno, Hector, Morais, Joao, Sibbing, Dirk, Rocca, Bianca, Hsieh, Ming-Hsiung, Akoum, Nazem, Lockwood, Deborah, Gomez Flores, Jorge Rafael, Jardine, Ronald, Fysiologie, MUMC+: MA Cardiologie (9), Cardiologie, RS: CARIM - R2.01 - Clinical atrial fibrillation, RS: Carim - H01 Clinical atrial fibrillation, Éducation Éthique Santé EA 7505 (EES), Université de Tours (UT), Université Paris Descartes - Paris 5 (UPD5), Hôtel-Dieu, Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Centre cardiologique du Nord (CCN), Griset SA, Diehl - Griset, Nouvelles Cliniques Nantaises, Service de Cardiologie (BREST - Cardio), Centre Hospitalier Régional Universitaire de Brest (CHRU Brest), Service de cardiologie, Université de la Méditerranée - Aix-Marseille 2-Assistance Publique - Hôpitaux de Marseille (APHM)- Hôpital de la Timone [CHU - APHM] (TIMONE), Unité de Recherche sur les Maladies Cardiovasculaires, du Métabolisme et de la Nutrition = Research Unit on Cardiovascular and Metabolic Diseases (ICAN), Université Pierre et Marie Curie - Paris 6 (UPMC)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU), CHU Grenoble, Service de cardiologie [CHU HEGP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Européen Georges Pompidou [APHP] (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO), Dysoxie, suractivité : aspects cellulaires et intégratifs thérapeutiques (DS-ACI / UMR MD2), Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Département de Cardiologie [Hôpital de la Timone - APHM], Assistance Publique - Hôpitaux de Marseille (APHM)- Hôpital de la Timone [CHU - APHM] (TIMONE), Centre recherche en CardioVasculaire et Nutrition = Center for CardioVascular and Nutrition research (C2VN), Institut National de la Recherche Agronomique (INRA)-Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Hôpital cardiologique, Université de Lille, Droit et Santé-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Optimisation des régulations physiologiques (ORPHY (EA 4324)), Université de Brest (UBO)-Centre Hospitalier Régional Universitaire de Brest (CHRU Brest)-Institut Brestois Santé Agro Matière (IBSAM), Université de Brest (UBO)-Université de Brest (UBO), Sorbonne Université (SU), CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), IHU-LIRYC, Université Bordeaux Segalen - Bordeaux 2-CHU Bordeaux [Bordeaux], Cardiac Stimulation and Rhythmology, University of Liverpool, Aalborg University [Denmark] (AAU), Lukaskrankenhaus, Technische Universität Munchen - Université Technique de Munich [Munich, Allemagne] (TUM), Universidad Nacional de Córdoba [Argentina], San Gerardo Hospital of Monza, Universidad de Murcia, S. Maria delle Croci Hospital, University of Sheffield [Sheffield], University of Bern, Sigmund Freud University (SFU), University of Belgrade [Belgrade], Department of Physiology, Maastricht University, Department of Physiology, Maastricht University [Maastricht]-Maastricht University [Maastricht], University hospital of Zurich [Zurich], and ESC Sci Document Grp

Subjects
Cardiac Catheterization, medicine.medical_treatment, Heart Valve Diseases, ELUTING STENT IMPLANTATION, 030204 cardiovascular system & hematology, VITAMIN-K ANTAGONIST, Left atrial appendage occlusion, Coronary artery disease, [SHS]Humanities and Social Sciences, Percutaneous coronary intervention, 0302 clinical medicine, HAS-BLED SCORES, Risk Factors, Stent, ST-SEGMENT ELEVATION, Position paper, 030212 general & internal medicine, Myocardial infarction, Consensus document, 610 Medicine & health, Stroke, ComputingMilieux_MISCELLANEOUS, BARE-METAL STENTS, European Heart Rhythm Association, AORTIC-VALVE IMPLANTATION, Low molecular weight heparin, Antiplatelet agents, DUAL ANTIPLATELET THERAPY, Atrial fibrillation, Acute coronary syndrome, Anticoagulation, Antithrombotic therapy, Bleeding, Non-Vitamin K antagonist oral anticoagulants, Parenteral anticoagulants, Thromboembolism, Thrombosis, Vitamin K antagonists, Cardiology and Cardiovascular Medicine, Physiology (medical), BLEEDING RISK SCORES, Treatment Outcome, UNINTERRUPTED ORAL ANTICOAGULATION, ACUTE MYOCARDIAL-INFARCTION, medicine.medical_specialty, Consensus, Settore BIO/14 - FARMACOLOGIA, medicine.drug_class, Hemorrhage, Risk Assessment, 03 medical and health sciences, Fibrinolytic Agents, medicine, Humans, Intensive care medicine, business.industry, Anticoagulants, ta3121, medicine.disease, Non-vitamin K antagonist oral anticoagulants, Human medicine, business, Platelet Aggregation Inhibitors
Abstract

In 2014, a joint consensus document dealing with the management of antithrombotic therapy in atrial fibrillation (AF) patients presenting with acute coronary syndrome (ACS) and/or undergoing percutaneous coronary or valve interventions was published, which represented an effort of the European Society of Cardiology Working Group on Thrombosis, European Heart Rhythm Association (EHRA), European Association of Percutaneous Cardiovascular Interventions (EAPCI), and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS) and Asia-Pacific Heart Rhythm Society (APHRS). Since publication of this document, additional data from observational cohorts, randomized controlled trials, and percutaneous interventions as well as new guidelines have been published. Moreover, new drugs and devices/interventions are also available, with an increasing evidence base. The approach to managing AF has also evolved towards a more integrated or holistic approach. In recognizing these advances since the last consensus document, EHRA, WG Thrombosis, EAPCI, and ACCA, with additional contributions from HRS, APHRS, Latin America Heart Rhythm Society (LAHRS), and Cardiac Arrhythmia Society of Southern Africa (CASSA), proposed a focused update, to include the new data, with the remit of comprehensively reviewing the available evidence and publishing a focused update consensus document on the management of antithrombotic therapy in AF patients presenting with ACS and/or undergoing percutaneous coronary or valve interventions, and providing up-to-date consensus recommendations for use in clinical practice.

Published
2019

4. ADHERE: randomized controlled trial comparing renal function in de novo kidney transplant recipients receiving prolonged-release tacrolimus plus mycophenolate mofetil or sirolimus

Author

Rummo, Oleg O., Carmellini, Mario, Rostaing, Lionel, Oberbauer, Rainer, Christiaans, Maarten H. L., Mousson, Christiane, Langer, Robert M., Citterio, Franco, Charpentier, Bernard, Brown, Malcolm, Kazeem, Gbenga, Lehner, Frank, Heer, Munish, Lim, Wai, Mühlbacher, Ferdinand, Pratschke, Johann, Bonvoisin, Cathérine, Kuypers, Dirk, Dedochova, Jarmila, Kuman, Milan, Le Meur, Yann, Deteix, Patrice, Frimat, Luc, Lang, Philippe, Lebranchu, Yvon, Legendre, Christophe, Westeel, Pierre Francois, Schenker, Peter, Hilgers, Karl-Friedrich, Witzke, Oliver, Hauser, Ingeborg, Kliem, Volker, Zeier, Martin, Kunzendorf, Ulrich, Bartels, Michael, Jonas, Sven, Guba, Markus, Wolters, Heiner H., Chan, Tak-Mao, Caputo, Flavia, Sparacino, Vito, Nowicki, Michal, Glyda, Maciej, Kim, Yu Seun, Jongwon, Ha, Kim, Chan Duck, Han, Duck Jong, Kim, Yeong Hoon, Perlin, Dmitry, Sal'Mayer, Alexander, Semchenko, Sergey B., Nesterenko, Igor, Franco, Antonio, Grinyó, Josep, Inza, Ainhoa, Ruiz, Juan Carlos, Chiang, Yang-Jen, Lee, Po-Chang, Suleymanlar, Gultekin, Sevmis, Sinasi, Kacar, Serdar, Republican Scientific and Practical Center (RSPC) for organ and Tissue Transplantation, Minsk, Republican Scientific and Practical Center (RSPC) for Organ and Transplantation, Department of Medical, Surgical and Neuroscience, University of Siena, Policlinico 'Santa Maria alle Scotte', Service de Néphrologie - Hypertension Artérielle Dialyse - Transplantation, CHU Toulouse [Toulouse]-Hôpital de Rangueil, CHU Toulouse [Toulouse], Department of Internal Medicine III, Medizinische Universität Wien = Medical University of Vienna, Department of Internal Medicine/Division of Nephrology, Maastrich, Maastricht University Medical Centre (MUMC), Maastricht University [Maastricht]-Maastricht University [Maastricht], Service de néphrologie (CHU de Dijon), Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Department of Chemical Engineering (DCE-MIT), Massachusetts Institute of Technology (MIT), Department of Surgery , Renal Transplantation, Rome, Catholic University, Rome, Ingénierie Moléculaire et Physiopathologie Articulaire (IMoPA), Université de Lorraine (UL)-Centre National de la Recherche Scientifique (CNRS), Department of Internal Medicine, University of Michigan [Ann Arbor], University of Michigan System-University of Michigan System, Astellas Pharma Europe Ltd, Chertsey, Universität Bern [Bern], Universidad de Cantabria, Kuypers, Dirk, RS: NUTRIM - R3 - Respiratory & Age-related Health, MUMC+: MA Nefrologie (9), Interne Geneeskunde, and RS: NUTRIM - R3 - Chronic inflammatory disease and wasting

Subjects
Graft Rejection, Male, Time Factors, Settore MED/18 - CHIRURGIA GENERALE, MULTICENTER, 030232 urology & nephrology, 030230 surgery, Kidney Function Tests, GLOMERULAR-FILTRATION-RATE, Kidney Failure, 0302 clinical medicine, Adrenal Cortex Hormones, Clinical endpoint, Medicine, calcineurin antagonists, Chronic, Kidney transplantation, ComputingMilieux_MISCELLANEOUS, OUTCOMES, immunosuppression, Graft Survival, Middle Aged, 3. Good health, kidney clinical, Treatment Outcome, surgical procedures, operative, REJECTION, Tolerability, ALLOGRAFT RECIPIENTS, outcome, [SDV.IMM]Life Sciences [q-bio]/Immunology, Female, WITHDRAWAL, Immunosuppressive Agents, Glomerular Filtration Rate, medicine.drug, Adult, medicine.medical_specialty, Urology, Renal function, Tacrolimus, Mycophenolic acid, 03 medical and health sciences, Transplantation, Humans, EXPOSURE, COMBINATION, Aged, Sirolimus, business.industry, Mycophenolic Acid, medicine.disease, Kidney Failure, Chronic, Transplant Recipients, Kidney Transplantation, Surgery, Discontinuation, INHIBITORS, business
Abstract

ADHERE was a randomized, open-label, Phase IV study comparing renal function at Week 52 postkidney transplant, in patients who received prolonged-release tacrolimus-based immunosuppressive regimens. On Days 0-27, patients received prolonged-release tacrolimus (initially 0.2 mg/kg/day), corticosteroids, and mycophenolate mofetil (MMF). Patients were randomized on Day 28 to receive either prolonged-release tacrolimus plus MMF (Arm 1) or prolonged-release tacrolimus (≥25% dose reduction on Day 42) plus sirolimus (Arm 2). The primary endpoint was glomerular filtration rate by iohexol clearance (mGFR) at Week 52. Secondary endpoints included eGFR, creatinine clearance (CrCl), efficacy failure (patient withdrawal or graft loss), and patient/graft survival. Tolerability was analyzed. The full-analysis set comprised 569 patients (Arm 1: 287; Arm 2: 282). Week 52 mean mGFR was similar in Arm 1 versus Arm 2 (40.73 vs. 41.75 ml/min/1.73 m(2) ; P = 0.405), as were the secondary endpoints, except composite efficacy failure, which was higher in Arm 2 versus 1 (18.2% vs. 11.5%; P = 0.002) owing to a higher postrandomization withdrawal rate due to adverse events (AEs) (14.4% vs. 5.2%). Results from this study show comparable renal function between arms at Week 52, with fewer AEs leading to study discontinuation with prolonged-release tacrolimus plus MMF (Arm 1) versus lower dose prolonged-release tacrolimus plus sirolimus (Arm 2). ispartof: Transplant International vol:30 issue:1 pages:83-95 ispartof: location:Switzerland status: published

Published
2017

5. Circulating ACE is a predictor of weight loss maintenance not only in overweight and obese women, but also in men

Author

Wang, P., Holst, C., Wodzig, W. K. W. H., Andersen, M. R., Astrup, A., Van Baak, M. A., Larsen, T. M., Jebb, S. A., Kafatos, A., Pfeiffer, A. F. H., Martinez, J. A., Handjieva-Darlenska, T., Kunesova, M., Viguerie, N., Langin, D., Saris, W. H. M., Mariman, E. C. M., Diogenes, Consortium, Department of Human Biology, NUTRIM School for Nutrition, Toxicology and Metabolism-Maastricht University Medical Centre (MUMC), Maastricht University [Maastricht]-Maastricht University [Maastricht], Institute of Preventive Medicine / Institut for Sygdomsforebyggelse, Copenhagen University Hospital-Frederiksberg Hospital Hovedvejen, Department of Clinical Chemistry, Maastricht University Medical Centre (MUMC), Department of Clinical Biochemistry, Copenhagen University Hospital, Department of Human Nutrition, Faculty of Life Science [Copenhagen], University of Copenhagen = Københavns Universitet (KU)-University of Copenhagen = Københavns Universitet (KU), Elsie Widdowson Laboratory, MRC Human Nutrition Research, Department of Social Medicine, Preventive Medicine and Nutrition Clinic, University of Crete [Heraklion] (UOC), Department of Clinical Nutrition, German Institute of Human Nutrition, Department of Endocrinology, Diabetes and Nutrition, Charité - UniversitätsMedizin = Charité - University Hospital [Berlin], Department of Physiology and Nutrition, Universidad de Navarra [Pamplona] (UNAV), Department of Nutrition, Dietetics and Metabolic Diseases, National Multiprofile Transport Hospital, Obesity Management Centre, Institute of Endocrinology, Obesity Research Laboratory, Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-CHU Toulouse [Toulouse]-Hôpital de Rangueil, CHU Toulouse [Toulouse], Department of Human Biology Nutrition and Toxicology Research (Diogenes), Maastricht University [Maastricht]-Institute Maastricht (NUTRIM), Humane Biologie, MUMC+: DA CDL Algemeen (9), RS: NUTRIM - R4 - Gene-environment interaction, RS: NUTRIM - R1 - Metabolic Syndrome, Simon, Marie Francoise, University of Copenhagen = Københavns Universitet (UCPH)-University of Copenhagen = Københavns Universitet (UCPH), Institut des Maladies Métaboliques et Cardiovasculaires (I2MC), and Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM)

Subjects
Male, Cross-sectional study, Endocrinology, Diabetes and Metabolism, Medicine (miscellaneous), MESH: Energy Intake, 030204 cardiovascular system & hematology, Overweight, Weight Gain, 0302 clinical medicine, Weight loss, MESH: Obesity, 2. Zero hunger, [SDV.MHEP.EM] Life Sciences [q-bio]/Human health and pathology/Endocrinology and metabolism, MESH: Diet, Reducing, 0303 health sciences, Nutrition and Dietetics, MESH: Middle Aged, MESH: Sex Distribution, Middle Aged, [SDV.MHEP.EM]Life Sciences [q-bio]/Human health and pathology/Endocrinology and metabolism, MESH: Predictive Value of Tests, 3. Good health, MESH: Weight Gain, Female, medicine.symptom, Adult, medicine.medical_specialty, Diet, Reducing, Peptidyl-Dipeptidase A, 03 medical and health sciences, MESH: Weight Loss, MESH: Cross-Sectional Studies, Predictive Value of Tests, Internal medicine, Weight Loss, medicine, Humans, Obesity, Sex Distribution, 030304 developmental biology, MESH: Humans, business.industry, MESH: Biological Markers, MESH: Adult, Odds ratio, Anthropometry, Confidence interval, MESH: Male, MESH: Peptidyl-Dipeptidase A, Endocrinology, Cross-Sectional Studies, business, Energy Intake, Weight gain, Body mass index, MESH: Female, Biomarkers
Abstract

BACKGROUND:Circulating angiotensin-converting enzyme (ACE) was identified as a predictor of weight loss maintenance in overweight/obese women of the Diogenes project.OBJECTIVE:To investigate whether ACE acted also as a predictor in men of the Diogenes study and to compare it with that in women.DESIGN:Subjects, who lost >/=8% of body weight induced by low-caloric diet in an 8-week weight loss period, were assigned to weight loss maintenance with dietary intervention for 6 months.SUBJECTS:125 overweight/obese healthy men from eight European countries who completed whole intervention.MEASUREMENTS:Concentrations and activity of serum ACE at baseline and after the 8-week weight loss, in addition to anthropometric and physiological parameters.RESULTS:Serum ACE concentration decreased by 11.3+/-10.6% during the weight loss period in men. A greater reduction is associated with less body weight regain during the maintenance period (r=0.227, P=0.012). ACE change was able to predict a weight regain

Published
2012

6. Implementation of trastuzumab in conjunction with adjuvant chemotherapy in the treatment of non-metastatic breast cancer in the Netherlands

Author

L. de Munck, Phb Willemse, Michael Schaapveld, Jelle Wesseling, Sabine Siesling, Renée Otter, Adri C. Voogd, Vivianne C. G. Tjan-Heijnen, Epidemiologie, Interne Geneeskunde, RS: CAPHRI School for Public Health and Primary Care, RS: GROW - School for Oncology and Reproduction, Department of Research, Comprehensive Cancer Centre North East, Department of Psychosocial Research and Epidemiology, The Netherlands Cancer Institute – Antoni van Leeuwenhoek Hospital, Department of Health Technology & Services Research, University of Twente [Netherlands], Department of Pathology, Department of Epidemiology, GROW - School for Oncology and Developmental Biology, Maastricht University Medical Centre (MUMC), Maastricht University [Maastricht]-Maastricht University [Maastricht], Comprehensive Cancer Centre South (CCCS), Division of Medical Oncology, Department of Internal Medicine, GROW - School for Oncology and Developmental Biology, Department of Medical Oncology, University Medical Centre Groningen, and Faculty of Behavioural, Management and Social Sciences

Subjects
Adult, Oncology, Cancer Research, medicine.medical_specialty, Receptor, ErbB-2, Adjuvant chemotherapy, IR-77770, medicine.medical_treatment, Antineoplastic Agents, Breast Neoplasms, Disease, ONCOGENE, Guideline, Antibodies, Monoclonal, Humanized, Young Adult, 03 medical and health sciences, 0302 clinical medicine, Breast cancer, Trastuzumab, Internal medicine, HER2, medicine, Humans, Non metastatic, 030212 general & internal medicine, skin and connective tissue diseases, neoplasms, Adjuvant, Aged, Netherlands, Aged, 80 and over, business.industry, Antibodies, Monoclonal, Middle Aged, medicine.disease, 3. Good health, Cancer registry, Chemotherapy, Adjuvant, HER-2, 030220 oncology & carcinogenesis, Female, METIS-277775, business, medicine.drug
Abstract

International audience; Trastuzumab in conjunction with adjuvant chemotherapy markedly improves outcome. In the Netherlands, a national guideline was released in September 2005 stating that trastuzumab should be given in conjunction with adjuvant chemotherapy in women with HER2-positive breast cancer. Aim of this study was to identify the number of women with HER2-positive breast cancer and to evaluate the level of implementation of adjuvant trastuzumab in clinical practice nationwide. Women diagnosed with primary breast cancer between September 2005 and January 2007 were selected from the Netherlands Cancer Registry (NCR). HER2 status, adjuvant treatment and reasons to withhold trastuzumab were registered. 14,934 Breast cancer patients were diagnosed in this period of whom 1,928 (13%) had a HER2-positive tumour. Of all HER2-positive women receiving adjuvant chemotherapy, 66 (6%) did not receive trastuzumab. This percentage decreased from 10% at the time of introduction of the guideline to 4% in the study period September 2005-December 2006. Most common reasons to withhold trastuzumab were cardiovascular disease (29%) and patient refusal (21%). Of all HER2-positive patients who received adjuvant chemotherapy, 94% received trastuzumab. The implementation of trastuzumab in clinical practice was realized within 8 months after introduction of the new guideline.

Published
2011

7. Computer-aided detection in full-field digital mammography in a clinical population: performance of radiologist and technologists

Author

Carla Boetes, Jos M. A. van Engelshoven, Alphons G.H. Kessels, Karin Flobbe, Frank J.H.M. van den Biggelaar, Department of Radiology, Maastricht University Medical Centre (MUMC), Maastricht University [Maastricht]-Maastricht University [Maastricht], Department of Clinical Epidemiology and Medical Technology Assessment, Beeldvorming, Epidemiologie, MUMC+: KIO Kemta (9), and RS: GROW - School for Oncology and Reproduction

Subjects
Adult, Cancer Research, medicine.medical_specialty, Digital mammography, Health Personnel, Performance, Population, CAD, Breast Neoplasms, Sensitivity and Specificity, Young Adult, Breast cancer, Sensitivity, medicine, Mammography, Humans, False Positive Reactions, cardiovascular diseases, education, Aged, Aged, 80 and over, Computer-aided detection, education.field_of_study, medicine.diagnostic_test, business.industry, Middle Aged, medicine.disease, Cad system, Full field digital mammography, Computer aided detection, Oncology, Radiologist, Specificity, Radiographic Image Interpretation, Computer-Assisted, Female, Radiology, business, Software, Technologist
Abstract

International audience; The purpose of the study was to evaluate the impact of a computer-aided detection (CAD) system on the performance of mammogram readers in interpreting digital mammograms in a clinical population. Furthermore, the ability of a CAD system to detect breast cancer in digital mammography was studied in comparison to the performance of radiologists and technologists as mammogram readers. Digital mammograms of 1,048 consecutive patients were evaluated by a radiologist and three technologists. Abnormalities were recorded and an imaging conclusion was given as a BI-RADS score before and after CAD analysis. Pathology results during 12 months follow up were used as a reference standard for breast cancer. Fifty-one malignancies were found in 50 patients. Sensitivity and specificity were computed before and after CAD analysis and provided with 95% CIs. In order to assess the detection rate of malignancies by CAD and the observers, the pathological locations of these 51 breast cancers were matched with the locations of the CAD marks and the mammographic locations that were considered to be suspicious by the observers. For all observers, the sensitivity rates did not change after application of CAD. A mean sensitivity of 92% was found for all technologists and 84% for the radiologist. For two technologists, the specificity decreased (from 84 to 83% and from 77 to 75%). For the radiologist and one technologist, the application of CAD did not have any impact on the specificity rates (95 and 83%, respectively). CAD detected 78% of all malignancies. Five malignancies were indicated by CAD without being noticed as suspicious by the observers. In conclusion, the results show that systematic application of CAD in a clinical patient population failed to improve the overall sensitivity of mammogram interpretation by the readers and was associated with an increase in false-positive results. However, CAD marked five malignancies that were missed by the different readers.

Published
2010

8. Physical activity and the risk of breast cancer in BRCA1/2 mutation carriers

Author

Senno Verhoef, Christi J. van Asperen, Charlotte J. Dommering, Peggy Manders, J. Margriet Collée, Flora E. van Leeuwen, Matti A. Rookus, Anouk Pijpe, Margreet G. E. M. Ausems, Hans F. A. Vasen, Richard M. Brohet, Encarna B. Gomez-Garcia, Laura J. van't Veer, Cora M. Aalfs, Nicoline Hoogerbrugge, Human Genetics, Department of Epidemiology, Netherlands Cancer Institute, Department of Human Genetics, Radboud University Medical Center [Nijmegen], Department of Research and Education, Spaarne hospital, Department of Clinical Genetics, Rotterdam Family Cancer Clinic, Erasmus University Medical Center [Rotterdam] (Erasmus MC), Family Cancer Clinic, The Netherlands Foundation for the Detection of Hereditary Tumours, Department of Clinical Genetics, Leiden University Medical Center (LUMC), Department of Clinical Genetics and Human Genetics, VU University Medical Center [Amsterdam], Department of Medical Genetics, University Medical Center [Utrecht], Academic Medical Center - Academisch Medisch Centrum [Amsterdam] (AMC), University of Amsterdam [Amsterdam] (UvA)-University of Amsterdam [Amsterdam] (UvA), Maastricht University Medical Centre (MUMC), Maastricht University [Maastricht]-Maastricht University [Maastricht], Department of Pathology, Human genetics, Epidemiology and Data Science, EMGO - Quality of care, Klinische Genetica, Genetica & Celbiologie, RS: GROW - School for Oncology and Reproduction, Clinical Genetics, and Internal Medicine

Subjects
Adult, Cancer Research, medicine.medical_specialty, Heterozygote, Genetics and epigenetic pathways of disease [NCMLS 6], Epidemiology, Population, Genes, BRCA2, Genes, BRCA1, Physical exercise, Breast Neoplasms, Molecular epidemiology [NCEBP 1], 03 medical and health sciences, 0302 clinical medicine, Breast cancer, SDG 3 - Good Health and Well-being, Risk Factors, BRCA1/2, Internal medicine, medicine, Humans, Risk factor, education, Exercise, HEBON, 030304 developmental biology, Gynecology, 0303 health sciences, education.field_of_study, Hereditary cancer and cancer-related syndromes [ONCOL 1], business.industry, Physical activity, Cancer, Retrospective cohort study, Middle Aged, medicine.disease, 3. Good health, Oncology, 030220 oncology & carcinogenesis, Mutation, Female, Breast disease, business, Cohort study
Abstract

Contains fulltext : 89737.pdf (Publisher’s version ) (Closed access) BRCA1/2 mutation carriers have a high lifetime risk of developing breast cancer. Differences in penetrance indicate that this risk may be influenced by lifestyle factors. Because physical activity is one of the few modifiable risk factors, it may provide a target to add to breast cancer prevention in this high-risk population. We examined the association between self-reported lifetime sports activity and breast cancer risk in a nationwide retrospective cohort study, including 725 carriers, of whom 218 had been diagnosed with breast cancer within 10 years prior to questionnaire completion. We found a nonsignificantly decreased risk for ever engaging in sports activity (HR = 0.84, 95%CI = 0.57-1.24). Among women who had participated in sports, a medium versus low level of intensity and duration (i.e., between 11.0 and 22.7 mean MET hours/week averaged over a lifetime) reduced the risk of breast cancer (HR = 0.59, 95%CI = 0.36-0.95); no dose-response trend was observed. For mean hours/week of sports activity, a nonsignificant trend was observed (HR(low versus never) = 0.93, 95%CI = 0.60-1.43; HR(medium versus never) = 0.81, 95%CI = 0.51-1.29; HR(high versus never) = 0.78, 95%CI = 0.48-1.29; p (trend overall) = 0.272; p (trend active women) = 0.487). For number of years of sports activity no significant associations were found. Among women active in sports before age 30, mean MET hours/week showed the strongest inverse association of all activity measures (HR(medium versus low) = 0.60, 95%CI = 0.38-0.96; HR(high versus low) = 0.58, 95%CI = 0.35-0.94; p (trend) = 0.053). Engaging in sports activity after age 30 was also inversely associated with breast cancer risk (HR = 0.63, 95%CI = 0.44-0.91). Our results indicate that sports activity may reduce the risk of breast cancer in BRCA1/2 mutation carriers. 01 februari 2010

Published
2010

9. In primary breast cancer the mitotic activity yields similar prognostic information as the histological grade: a study with long-term follow-up

Author

Huub Straatman, André L. M. Verbeek, Louk V.A.M. Beex, Peter Bult, Vivianne C. G. Tjan-Heijnen, Jan Willem H. Leer, Peggy Manders, J. Hendriks, Roland Holland, Department of Pathology, Radboud University Medical Center [Nijmegen], Department of Chemical Endocrinology, Department of Medical Oncology, Department of Human Genetics, Department of Epidemiology & Biostatistics, PHARMO, Institute for Drug Outcome Research, Division of Medical Oncology, Department of Internal Medicine, Maastricht University Medical Centre (MUMC), Maastricht University [Maastricht]-Maastricht University [Maastricht], National Expert and Training Centre for Breast Cancer Screening, Department of Radiotherapy, Interne Geneeskunde, Kindergeneeskunde, and RS: GROW - School for Oncology and Reproduction

Subjects
Adult, Chemical and physical biology [NCMLS 7], Cancer Research, medicine.medical_specialty, Prognostic variable, Mitotic index, medicine.medical_treatment, Breast Neoplasms, Kaplan-Meier Estimate, Aetiology, screening and detection [ONCOL 5], Gastroenterology, Molecular epidemiology [NCEBP 1], Breast cancer, Risk Factors, Translational research [ONCOL 3], Internal medicine, Mitotic Index, Humans, Medicine, Histological grade, Aged, Netherlands, Proportional Hazards Models, Retrospective Studies, Aged, 80 and over, Gynecology, business.industry, Carcinoma, Carcinoma, Ductal, Breast, Breast cancer mortality, Hazard ratio, Cancer, Histology, Middle Aged, Prognosis, medicine.disease, Mitotic activity, Oncology, Evaluation of complex medical interventions [NCEBP 2], Female, Breast disease, business, Adjuvant, Follow-Up Studies
Abstract

Contains fulltext : 88107.pdf (Publisher’s version ) (Closed access) We evaluated with long-term follow-up, the prognostic value of the mitotic activity index (MAI) and the volume corrected mitotic index (M/V-index) compared with that of the histological grade in breast cancer patients not treated with adjuvant systemic therapy. Of 739 consecutive patients living in the city of Nijmegen, the Netherlands, 477 patients with primary unilateral breast cancer were not treated with adjuvant systemic therapy and eligible for the study. In multivariate survival analyses the MAI and M/V-index showed similar hazard ratios (HRs) compared to HRs of histological grade for overall survival (OS) (HR: 1.45, 1.48, and grade II versus grade I (GII/GI) 1.34, grade III versus grade I (GIII/GI) 1.53, respectively) and for breast cancer specific survival (BCSS) (HR: 1.27, 1.57, and (GII/GI) 1.57 (GIII/GI) 2.32, respectively). Other independent prognostic variables for OS and BCSS were age at diagnosis, tumour size, and number of positive lymph nodes. In the present study with long term follow-up, we compared the prognostic value of mitotic activity with that of histological grade and found no advantage for the mitotic activity in predicting either BCSS or OS and concluded that histological grade and the mitotic activity were equally informative in predicting patient outcome. As histological grade is a well established and widely used prognosticator we do not have arguments to replace the histological grade by the mitotic indices MAI or M/V-index. 01 juli 2010

Published
2009

10. Patient-specific modelling of cardiac electrophysiology in heart-failure patients

Author

Stefano Muzzarelli, Mark Potse, Angelo Auricchio, Romina Murzilli, Frits W. Prinzen, Enrico G. Caiani, Rolf Krause, Wilco Kroon, François Regoli, Dorian Krause, University of Zurich, Potse, Mark, Modélisation et calculs pour l'électrophysiologie cardiaque (CARMEN), IHU-LIRYC, Université Bordeaux Segalen - Bordeaux 2-CHU Bordeaux [Bordeaux]-Université Bordeaux Segalen - Bordeaux 2-CHU Bordeaux [Bordeaux]-Institut de Mathématiques de Bordeaux (IMB), Université Bordeaux Segalen - Bordeaux 2-Université Sciences et Technologies - Bordeaux 1-Université de Bordeaux (UB)-Institut Polytechnique de Bordeaux (Bordeaux INP)-Centre National de la Recherche Scientifique (CNRS)-Université Sciences et Technologies - Bordeaux 1-Université de Bordeaux (UB)-Institut Polytechnique de Bordeaux (Bordeaux INP)-Centre National de la Recherche Scientifique (CNRS)-Inria Bordeaux - Sud-Ouest, Institut National de Recherche en Informatique et en Automatique (Inria)-Institut National de Recherche en Informatique et en Automatique (Inria), Center for Computational Medicine in Cardiology (CCMC), Università della Svizzera italiana = University of Italian Switzerland (USI), Institute of Computational Science, Cardiocentro Ticino [Lugano], Universität Zürich [Zürich] = University of Zurich (UZH), Department of Bioengineering [Politecnico Milano], Politecnico di Milano [Milan] (POLIMI), Department of Physiology, Maastricht University, Department of Physiology, Maastricht University [Maastricht]-Maastricht University [Maastricht], Institut de Mathématiques de Bordeaux (IMB), Université Bordeaux Segalen - Bordeaux 2-Université Sciences et Technologies - Bordeaux 1 (UB)-Université de Bordeaux (UB)-Institut Polytechnique de Bordeaux (Bordeaux INP)-Centre National de la Recherche Scientifique (CNRS)-Université Bordeaux Segalen - Bordeaux 2-Université Sciences et Technologies - Bordeaux 1 (UB)-Université de Bordeaux (UB)-Institut Polytechnique de Bordeaux (Bordeaux INP)-Centre National de la Recherche Scientifique (CNRS)-Inria Bordeaux - Sud-Ouest, Institut National de Recherche en Informatique et en Automatique (Inria)-Institut National de Recherche en Informatique et en Automatique (Inria)-IHU-LIRYC, Université Bordeaux Segalen - Bordeaux 2-CHU Bordeaux [Bordeaux]-CHU Bordeaux [Bordeaux], Fysiologie, and RS: CARIM - R2 - Cardiac function and failure

Subjects
Male, Action Potentials, 02 engineering and technology, 030204 cardiovascular system & hematology, Ventricular Function, Left, Electrocardiography, 0302 clinical medicine, 2737 Physiology (medical), Heart Rate, medicine.diagnostic_test, Cardiac electrophysiology, Left bundle branch block, Models, Cardiovascular, Articles, Left bundle-branch block, Cardiology, Female, Electrical conduction system of the heart, Electrophysiologic Techniques, Cardiac, Cardiology and Cardiovascular Medicine, medicine.medical_specialty, Bundle-Branch Block, 0206 medical engineering, 610 Medicine & health, 11171 Cardiocentro Ticino, 2705 Cardiology and Cardiovascular Medicine, 03 medical and health sciences, [SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, Heart Conduction System, Predictive Value of Tests, Physiology (medical), Internal medicine, Heart rate, medicine, Humans, Computer Simulation, cardiovascular diseases, Endocardium, Aged, Heart Failure, Bundle branch block, business.industry, Computer models, Numerical Analysis, Computer-Assisted, medicine.disease, 020601 biomedical engineering, Heart failure, business, Conduction disorders
Abstract

Aims Left-ventricular (LV) conduction disturbances are common in heart-failure patients and a left bundle-branch block (LBBB) electrocardiogram (ECG) type is often seen. The precise cause of this pattern is uncertain and is probably variable between patients, ranging from proximal interruption of the left bundle branch to diffuse distal conduction disease in the working myocardium. Using realistic numerical simulation methods and patient-tailored model anatomies, we investigated different hypotheses to explain the observed activation order on the LV endocardium, electrogram morphologies, and ECG features in two patients with heart failure and LBBB ECG. Methods and results Ventricular electrical activity was simulated using reaction-diffusion models with patient-specific anatomies. From the simulated action potentials, ECGs and cardiac electrograms were computed by solving the bidomain equation. Model parameters such as earliest activation sites, tissue conductivity, and densities of ionic currents were tuned to reproduce the measured signals. Electrocardiogram morphology and activation order could be matched simultaneously. Local electrograms matched well at some sites, but overall the measured waveforms had deeper S-waves than the simulated waveforms. Conclusion Tuning a reaction-diffusion model of the human heart to reproduce measured ECGs and electrograms is feasible and may provide insights in individual disease characteristics that cannot be obtained by other means.

Published
2014

11. Body weight and risk of breast cancer in BRCA1/2 mutation carriers

Author

Manders, P., Pijpe, A., Hooning, M.J., Kluijt, I., Vasen, H.F., Hoogerbrugge, N., Asperen, C.J. van, Meijers-Heijboer, H., Ausems, M.G., Os, T.A. van, Gomez-Garcia, E.B., Brohet, R.M., Leeuwen, F.E. van, Rookus, M.A., Ligtenberg, M.J.L., Clinical Genetics, Medical Oncology, Internal Medicine, Human genetics, VU University medical center, EMGO - Quality of care, CCA - Innovative therapy, Klinische Genetica, RS: GROW - School for Oncology and Reproduction, Department of Epidemiology, Netherlands Cancer Institute, Department of Human Genetics, Radboud University Medical Center [Nijmegen], Department of Medical Oncology, Erasmus University Medical Center [Rotterdam] (Erasmus MC), Family Cancer Clinic, The Netherlands Foundation for the Detection of Hereditary Tumours, Poortgebouw Zuid, Department of Clinical Genetics, Leiden University Medical Center (LUMC), Department of Clinical Genetics and Human Genetics, VU University Medical Center [Amsterdam], Department of Medical Genetics, University Medical Center [Utrecht], Academic Medical Center - Academisch Medisch Centrum [Amsterdam] (AMC), University of Amsterdam [Amsterdam] (UvA)-University of Amsterdam [Amsterdam] (UvA), Maastricht University Medical Centre (MUMC), Maastricht University [Maastricht]-Maastricht University [Maastricht], Department of Research and Education, Spaarne hospital, University of Groningen, and Human Genetics

Subjects
Cancer Research, Epidemiology, Overweight, SUSCEPTIBILITY, Weight Gain, Polymerase Chain Reaction, Body Mass Index, Cohort Studies, 0302 clinical medicine, Breast cancer, Risk Factors, Netherlands, 2. Zero hunger, 0303 health sciences, education.field_of_study, Obstetrics, BRCA1 Protein, Genetic Carrier Screening, WOMEN, DNA, Neoplasm, Middle Aged, Prognosis, 3. Good health, Postmenopause, Survival Rate, Oncology, 030220 oncology & carcinogenesis, OBESITY, Female, LIFE-STYLE, Breast disease, medicine.symptom, Adult, medicine.medical_specialty, Population, Hereditary cancer and cancer-related syndromes Genetics and epigenetic pathways of disease [ONCOL 1], Breast Neoplasms, Body weight Breast cancer BRCA1/2 HEBON Epidemiology ovarian-cancer estrogen-receptor physical-activity life-style mass index geo-hebon obesity cohort women susceptibility, OVARIAN-CANCER, 03 medical and health sciences, Young Adult, MASS INDEX, SDG 3 - Good Health and Well-being, BRCA1/2, medicine, Humans, COHORT, Risk factor, education, HEBON, 030304 developmental biology, Retrospective Studies, Gynecology, BRCA2 Protein, Hereditary cancer and cancer-related syndromes [ONCOL 1], business.industry, Cancer, Body weight, medicine.disease, ESTROGEN-RECEPTOR, PHYSICAL-ACTIVITY, Premenopause, GEO-HEBON, Case-Control Studies, Mutation, Hereditary cancer and cancer-related syndromes Genomic disorders and inherited multi-system disorders [ONCOL 1], business, Weight gain, Body mass index
Abstract

Contains fulltext : 95679.pdf (Publisher’s version ) (Closed access) Obesity is an established risk factor for postmenopausal breast cancer in the general population. However, it is still unclear whether this association also exists in BRCA1/2 mutation carriers. We investigated the association between self-reported anthropometric measures and breast cancer risk in a nationwide retrospective cohort study, including 719 BRCA1/2 carriers, of whom 218 had been diagnosed with breast cancer within 10 years prior to questionnaire completion. All time-varying Cox proportional hazards analyses were stratified by menopausal status. For premenopausal breast cancer, no statistically significant associations were observed for any of the anthropometric measures. The association between body mass index (BMI) at age 18 and premenopausal breast cancer risk suggested a trend of decreasing risk with increasing BMI (HR(22.50-24.99 vs. 18.50-22.49) = 0.83, 95% CI = 0.47-1.44 and HR(>/= 25.00 vs. 18.50-22.49) = 0.41, 95% CI = 0.13-1.27). For postmenopausal breast cancer, being 1.67 m and taller increased the risk 1.7-fold (HR = 1.67, 95% CI = 1.01-2.74) when compared to a height /= 72 kg increased the risk of postmenopausal breast cancer 2.1-fold (95% CI = 1.23-3.59). A current BMI of >/= 25.0 kg/m(2), an adult weight gain of 5 kg or more, and a relative adult weight gain of 20% or more were all non-significantly associated with a 50-60% increased risk of postmenopausal breast cancer [HR = 1.46 (0.86-2.51), HR = 1.56 (95% CI = 0.85-2.87), and HR = 1.60 (95% CI = 0.97-2.63), respectively], when compared with having a healthy or stable weight. No associations for body weight or BMI at age 18 were observed. In conclusion, menopausal status seemed to modify the association between body weight and breast cancer risk among BRCA1/2 carriers. We observed no clear association between body weight and premenopausal breast cancer, while overweight and weight gain increased postmenopausal breast cancer risk. Carriers may reduce their risk of postmenopausal breast cancer by maintaining a healthy body weight throughout life.

Published
2011

12. Variation in management of early breast cancer in the Netherlands, 2003-2006

Author

J.W.W. Coebergh, M.L.E.A. Jansen-Landheer, Henk Struikmans, Michel W.J.M. Wouters, Vivianne C. G. Tjan-Heijnen, L.V. van de Poll-Franse, C.J.H. van de Velde, L.N. van Steenbergen, Interne Geneeskunde, RS: GROW - School for Oncology and Reproduction, Public Health, Medical and Clinical Psychology, Comprehensive Cancer Centre South, Tilburg University [Tilburg], Netspar, Dept. of Surgery, Antoni van Leeuwenhoek Hospital, Comprehensive Cancer Centre Amsterdam, Dept. of Public Health, Erasmus University Medical Centre, Dept. of Radiotherapy, Leiden University Medical Center (LUMC), Medical Centre Haaglanden, Dept. of Internal Medicine, Maastricht University Medical Centre (MUMC), and Maastricht University [Maastricht]-Maastricht University [Maastricht]

Subjects
sentinel lymph node procedure, medicine.medical_treatment, Segmental, Mastectomy, Segmental, Breast-conserving surgery, Registries, Non-U.S. Gov't, Mastectomy, Adjuvant, Netherlands, Research Support, Non-U.S. Gov't, General Medicine, Sentinel node, Middle Aged, Combined Modality Therapy, Hospitals, Treatment Outcome, Oncology, Lymphatic Metastasis, Female, Adult, medicine.medical_specialty, Breast surgery, Antineoplastic Agents, Breast Neoplasms, Research Support, breast conserving surgery, Breast cancer, SDG 3 - Good Health and Well-being, Internal medicine, medicine, Journal Article, Humans, early breast cancer, axillary lymph node dissection, Aged, Neoplasm Staging, Gynecology, Radiotherapy, business.industry, Sentinel Lymph Node Biopsy, Axillary Lymph Node Dissection, medicine.disease, Cancer registry, Radiation therapy, Logistic Models, Axilla, Lymph Node Excision, Surgery, Radiotherapy, Adjuvant, adjuvant systemic therapy, business
Abstract

BACKGROUND: To describe variation in staging and primary treatment by hospital characteristics including type and volume and region in patients with early breast cancer (BC) in the Netherlands, 2003-2006 after completion of national guidelines in 2002.METHODS: All patients newly diagnosed with invasive BC in 2003-2006 and recorded in the Netherlands Cancer Registry were included (n = 51 354). Multivariable logistic regression analyses examined the influence of patient and hospital characteristics, also by region, on type of breast surgery, axillary lymph node dissection (ALND), sentinel node procedure (SNP), and adjuvant irradiation and/or systemic treatment.RESULTS: Patients CONCLUSION: With detailed evidence-based national guidelines since 2002 the considerable regional and hospital variation in staging procedures and primary treatment among newly diagnosed patients with early breast cancer in the Netherlands decreased markedly, suggesting the presence of late adaptors rather than specific hospital characteristics.

Published
2010

13. Are breast conservation and mastectomy equally effective in the treatment of young women with early breast cancer? Long-term results of a population-based cohort of 1,451 patients aged ≤40 years

Author

Grard A. P. Nieuwenhuijzen, M. Cathelijne B. J. E. Tutein Nolthenius-Puylaert, Rudi M. H. Roumen, Maurice J.C. van der Sangen, Adri C. Voogd, Philip Poortmans, Fenneke M. M. van de Wiel, Miranda F. Ernst, Vivianne C. G. Tjan-Heijnen, Department of Radiotherapy, Catharina Hospital, Faculty of Health, Medicine and Life Sciences, Maastricht University [Maastricht], Dr. Bernard Verbeeten Institute, Division of Medical Oncology, Department of Internal Medicine, Research Institute Growth and Development (GROW), Maastricht University Medical Centre (MUMC), Maastricht University [Maastricht]-Maastricht University [Maastricht], Department of Surgery, Máxima Medical Centre, Jeroen Bosch Hospital, Department of Pathology, Elkerliek Hospital, Department of Epidemiology, Research Institute Growth and Development (GROW), and Eindhoven Cancer Registry

Subjects
Adult, Cancer Research, medicine.medical_specialty, Survival, medicine.medical_treatment, Breast carcinoma, Breast Neoplasms, Systemic treatment, Mastectomy, Segmental, Cohort Studies, Young Adult, Breast cancer, Recurrence, Internal medicine, medicine, Humans, Young adult, Mastectomy, Neoplasm Staging, business.industry, Age Factors, Cancer, Breast conservation, medicine.disease, Prognosis, Combined Modality Therapy, Survival Analysis, Confidence interval, Surgery, Oncology, Local control, Female, Breast disease, business, Cohort study
Abstract

International audience; To compare the effectiveness of breast-conserving therapy (BCT) and mastectomy, all women aged ≤40 years, treated for early-stage breast cancer in the southern part of the Netherlands between 1988 and 2005, were identified. A total of 562 patients underwent mastectomy and 889 patients received BCT. During follow-up, 23 patients treated with mastectomy and 135 patients treated with BCT developed a local relapse without previous or simultaneous evidence of distant disease. The local relapse risk for patients treated with mastectomy was 4.4% (95% confidence interval (CI) 2.4-6.4) at 5 years and reached a plateau after 6 years at 6.0% (95% CI 3.5-8.5). After BCT, the 5-, 10- and 15-year risks were 8.3% (95% CI 6.3-10.5), 18.4% (95% CI 15.0-21.8) and 28.2% (95% CI 23.0-33.4), respectively (

Published
2010

14. Safety of avoiding routine use of axillary dissection in early stage breast cancer: a systematic review

Author

Maaike de Boer, Vivianne C. G. Tjan-Heijnen, George F. Borm, Paul J. van Diest, J.H.M.J. Vestjens, Marjolein L. Smidt, Manon J. Pepels, RS: NUTRIM - R2 - Gut-liver homeostasis, Interne Geneeskunde, Surgery, RS: GROW - School for Oncology and Reproduction, Division of Medical Oncology, Department of Internal Medicine, GROW - School for Oncology and Developmental Biology, Maastricht University Medical Centre (MUMC), Maastricht University [Maastricht]-Maastricht University [Maastricht], Department of Medical Oncology, Radboud University Medical Center [Nijmegen], Department of Surgery, GROW--School for Oncology and Developmental Biology, University Medical Centre Utrecht, University Medical Center [Utrecht], and Department of Epidemiology, Biostatistics and HTA

Subjects
Cancer Research, medicine.medical_specialty, Survival, SENTINEL-LYMPH-NODE, LONG-TERM, SURGERY, medicine.medical_treatment, Sentinel lymph node, Quality of nursing and allied health care [NCEBP 6], Breast Neoplasms, Axillary recurrence, Breast cancer, Axillary lymph node dissection, Clinical endpoint, Medicine, Humans, Survival rate, Radical mastectomy, Neoplasm Staging, 25-YEAR FOLLOW-UP, RECURRENCE RATE, business.industry, Sentinel Lymph Node Biopsy, Axillary Lymph Node Dissection, medicine.disease, Prognosis, REGIONAL RECURRENCE, Surgery, RANDOMIZED CLINICAL-TRIAL, Survival Rate, Oncology, Sentinel node, Evaluation of complex medical interventions [NCEBP 2], Lymphatic Metastasis, RADICAL-MASTECTOMY, BIOPSY, Lymph Node Excision, Lymphadenectomy, Female, Breast disease, Neoplasm Recurrence, Local, business
Abstract

Item does not contain fulltext Physicians are moving away from routine axillary lymph node dissection (ALND) in clinically node-negative breast cancer. We conducted a systemic review on the safety of this policy. Pubmed and Cochrane library were searched for. Sixty-eight studies were included: studies of clinically node-negative patients in the pre-sentinel node (SN) era; observational studies of SN-negative patients, without ALND; comparative studies of SN-negative patients, with a non-ALND and an ALND group; SN-positive studies, of patients without ALND. Primary endpoint was the pooled axillary recurrence rate (ARR) of each category; secondary endpoint was overall survival (OS) rate. In pre-SN studies, with larger tumors and less systemic therapy, ARR without ALND after 5-10 years follow-up was 12-18%, with 5% reduced OS. In the observational SN-negative studies, with median follow-up of 36 months, the pooled ARR was 0.6% (95% CI 0.6-0.8). In the comparative SN-negative studies, pooled ARR was 0.4% (95% CI 0.2-0.6) without ALND versus 0.3% (95% CI 0.1-0.6) with ALND at 31 and 47 months, respectively, and no survival disadvantage. In SN-positive studies, ARR was up to 1.7% (95% CI 1.0-2.7) at 30 months. For patients with an H&E positive SN the ARR without ALND was 5% after 23 months, which may imply rates as high as 13 and 18% after 5 and 8 years. In conclusion, this systematic review confirms the safety of omitting ALND in SN-negative patients. There is a potential role for avoiding ALND in selected SN-positive patients, but eligibility criteria and the role of systemic therapy need further to be elucidated.

Published
2010

15. Childhood and adolescent energy restriction and subsequent colorectal cancer risk: results from the Netherlands Cohort Study

Author

R Alexandra Goldbohm, Anton F.P.M. de Goeij, Laura A. E. Hughes, Adriaan P. de Bruïne, Piet A. van den Brandt, Manon van Engeland, Matty P. Weijenberg, Promovendi ODB, Epidemiologie, Pathologie, RS: CAPHRI School for Public Health and Primary Care, RS: GROW - School for Oncology and Reproduction, Epidemiology, Maastricht University [Maastricht], Department of Epidemiology, Prevention and Health, TNO Quality of Life, Pathology, Maastricht University Medical Centre (MUMC), and Maastricht University [Maastricht]-Maastricht University [Maastricht]

Subjects
Adult, Male, medicine.medical_specialty, Adolescent, Epidemiology, Colorectal cancer, Hunger, Lower risk, Young Adult, cohort studies, Residence Characteristics, Risk Factors, medicine, Humans, Body Weights and Measures, Prospective Studies, Risk factor, Prospective cohort study, Child, Exercise, Aged, Netherlands, business.industry, Smoking, starvation, General Medicine, Middle Aged, medicine.disease, Surgery, Diet, Socioeconomic Factors, Cohort, Medicine, adolescence, Female, caloric restriction, Risk assessment, business, Colorectal Neoplasms, Energy Intake, Cohort study, Demography
Abstract

Background: Energy restriction during childhood and adolescence is suggested to lower colorectal cancer (CRC) risk. We investigated this in the Netherlands Cohort Study. Methods: Information on diet and other risk factors was collected by a baseline questionnaire in 1986 when cohort members were 55-69 years of age (n = 120 852). Three indicators of early life exposure to energy restriction were assessed: father's employment status during the Economic Depression (1932-40), place of residence during Second World War years (1940-44) and the 'Hunger Winter' (1944-45), a severe famine. Using the case-cohort approach, incidence rate ratios (RRs) and 95% confidence intervals (CIs) were calculated for total colorectal, proximal colon, distal colon, rectosigmoid and rectal cancers, according to the three time periods of energy restriction. After 16.3 years of follow-up, 2573 cases were available for multivariate analyses. Results: Men who lived in a western city during the Hunger Winter and therefore exposed to the highest degree of energy restriction, had a lower risk of developing CRC (RR: 0.81, 95% CI: 0.68-0.98), and tumours of the proximal colon (RR: 0.72, 95% CI: 0.54-0.96) and rectum (RR: 0.71, 95% CI: 0.53-0.96). In women, non-statistically significant inverse associations were observed for tumours of the distal colon, rectosigmoid and rectum. Inverse associations were also observed between the other two exposure times and studied endpoints, though not statistically significant. Conclusions: This unique observational evidence suggests that severe energy restriction during childhood and adolescence may lower CRC risk, especially in men, thus providing insight regarding the role of energy intake during early life in CRC development. Published by Oxford University Press on behalf of the International Epidemiological Association © The Author 2010; all rights reserved.

Published
2010

16. Assessment of false-negative cases of breast MR imaging in women with a familial or genetic predisposition

Author

Jan G. M. Klijn, Claudette E. Loo, Theo Kok, E. Bergers, Adriana J. Rijnsburger, Inge-Marie Obdeijn, Martin N. J. M. Wasser, Carla Boetes, Department of Radiology, Erasmus University Medical Center [Rotterdam] (Erasmus MC), Department of Radiology, Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Department of Medical Oncology, Family Cancer Clinic, Leiden University Medical Center (LUMC), VU University Medical Center [Amsterdam], Groningen University Medical Center, Radboud University Medical Center [Nijmegen], Maastricht University Medical Centre (MUMC), Maastricht University [Maastricht]-Maastricht University [Maastricht], Beeldvorming, RS: FHML non-thematic output, Radiology & Nuclear Medicine, Medical Oncology, Radiology and nuclear medicine, and CCA - Innovative therapy

Subjects
Cancer Research, Breast cancer, Risk Factors, Mass Screening, skin and connective tissue diseases, False Negative Reactions, ULTRASOUND, Netherlands, medicine.diagnostic_test, BRCA1 Protein, Middle Aged, RESONANCE, Magnetic Resonance Imaging, CANCER, Pedigree, Gene Expression Regulation, Neoplastic, Hereditary, Oncology, CARCINOMA IN-SITU, Screening, Female, Radiology, Breast disease, Breast cancer MRI Screening Hereditary carcinoma in-situ high-risk diagnostic-accuracy mutation carriers brca2 mutations cancer mammography resonance surveillance ultrasound, MRI, Adult, medicine.medical_specialty, Breast Neoplasms, MUTATION CARRIERS, Malignancy, Risk Assessment, MAMMOGRAPHY, SDG 3 - Good Health and Well-being, Predictive Value of Tests, SURVEILLANCE, medicine, Genetic predisposition, Humans, Mammography, Genetic Predisposition to Disease, DIAGNOSTIC-ACCURACY, BRCA2 MUTATIONS, Retrospective Studies, BRCA2 Protein, business.industry, Carcinoma in situ, Cancer, Ductal carcinoma, medicine.disease, Surgery, HIGH-RISK, Carcinoma, Intraductal, Noninfiltrating, Mutation, Apoptosis Regulatory Proteins, business
Abstract

International audience; In order to assess the characteristics of malignant breast lesions those were not detected during screening by MR imaging. In the Dutch MRI screening study (MRISC), a non-randomized prospective multicenter study, women with high familial risk or a genetic predisposition for breast cancer were screened once a year by mammography and MRI and every 6 months with a clinical breast examination (CBE). The false-negative MR examinations were subject of this study and were retrospectively reviewed by two experienced radiologists. From November 1999 until March 2006, 2,157 women were eligible for study analyses. Ninety-seven malignant breast tumors were detected, including 19 DCIS (20%). In 22 patients with a malignant lesion, the MRI was assessed as BI-RADS 1 or 2. One patient was excluded because the examinations were not available for review. Forty-three percent (9/21) of the false-negative MR cases concerned pure ductal carcinoma in situ (DCIS) or DCIS with invasive foci, in eight of them no enhancement was seen at the review. In six patients the features of malignancy were missed or misinterpreted. Small lesion size ( = 3), extensive diffuse contrast enhancement of the breast parenchyma ( = 2), and a technically inadequate examination ( = 1) were other causes of the missed diagnosis. A major part of the false-negative MR diagnoses concerned non-enhancing DCIS, underlining the necessity of screening not only with MRI but also with mammography. Improvement of MRI scanning protocols may increase the detection rate of DCIS. The missed and misinterpreted cases are reflecting the learning curve of a multicenter study.

Published
2009

17. The impact of preoperative breast MRI on the re-excision rate in invasive lobular carcinoma of the breast

Author

Peter Bult, Ritse M. Mann, Carla Boetes, Theo Wobbes, Claudette E. Loo, Kenneth G. A. Gilhuijs, Jelle O. Barentsz, Beeldvorming, RS: GROW - School for Oncology and Reproduction, Department of Radiology, Radboud University Medical Center [Nijmegen], The Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Department of Surgery, Department of Pathology, Maastricht University Medical Centre (MUMC), Maastricht University [Maastricht]-Maastricht University [Maastricht], School for Oncology and Developmental Biology [Maastricht] (GROW), Maastricht University [Maastricht]-Maastricht University Medical Centre (MUMC), and Maastricht University [Maastricht]

Subjects
Adult, Reoperation, Cancer Research, medicine.medical_specialty, Time Factors, medicine.medical_treatment, Breast Neoplasms, Aetiology, screening and detection [ONCOL 5], Mastectomy, Segmental, Preoperative care, Risk Assessment, Breast cancer, Translational research [ONCOL 3], Predictive Value of Tests, Breast conserving surgery, Preoperative Care, Breast-conserving surgery, Odds Ratio, Medicine, Breast MRI, Humans, Neoplasm Invasiveness, skin and connective tissue diseases, Mastectomy, Aged, Netherlands, Retrospective Studies, Aged, 80 and over, medicine.diagnostic_test, business.industry, Retrospective cohort study, Middle Aged, medicine.disease, Invasive lobular carcinoma, Magnetic Resonance Imaging, Surgery, Carcinoma, Lobular, Treatment Outcome, Oncology, Female, Breast disease, Radiology, business, Re-excision rate
Abstract

Contains fulltext : 87794.pdf (Publisher’s version ) (Closed access) Re-excision rates after breast conserving surgery(BCS) of invasive lobular carcinoma (ILC) are high.Preoperative breast MRI has the potential to reduce re-excision rates, but may lead to an increased rate of mastectomies. Hence, we assessed the influence of preoperative breast MRI on the re-excision rate and the rate of mastectomies. We performed a retrospective cohort study of a consecutive series of patients with ILC who presented in one of two dedicated tertiary cancer centers between 1993 and 2005. We assessed the initial type of surgery(BCS or mastectomy), the re-excision rate and the final type of surgery. Patients were stratified into two groups:those who received preoperative MRI (MR? group) and those who did not (MR- group). In the MR- group, 27%of the patients underwent a re-excision after initial BCS. In the MR? group, this rate was significantly lower at 9%.The odds ratio was 3.64 (95% CI: 1.30-10.20, P = 0.010).There was a trend towards a lower final mastectomy rate in the MR? group compared to the MR- group (48 vs. 59%,P = 0.098). In conclusion, preoperative MRI in patients with ILC can reduce re-excision rates without increasing the rate of mastectomies. 01 januari 2010

Published
2009

18. Local recurrence in rectal cancer can be predicted by histopathological factors

Author

Regina G. H. Beets-Tan, R.C. Dresen, H.J.T. Rutten, Iris D. Nagtegaal, Grard A. P. Nieuwenhuijzen, J.H.J.M. van Krieken, T.B.J. Demeyere, Esther Peters, A. J. C. Van Den Brule, Alfons G. H. Kessels, Department of Surgery, Catharina Hospital Eindhoven, Department of Radiology, Maastricht University Medical Centre (MUMC), Maastricht University [Maastricht]-Maastricht University [Maastricht], Department of Pathology, Radboud University Medical Center [Nijmegen], Department of pathology, and Department of Epidemiology

Subjects
Adult, Male, medicine.medical_specialty, Age-related aspects of cancer [ONCOL 2], Genetics and epigenetic pathways of disease [NCMLS 6], Lymphovascular invasion, Colorectal cancer, lymphovascular invasion, Protective factor, Aetiology, screening and detection [ONCOL 5], Logistic regression, Gastroenterology, Translational research [ONCOL 3], Internal medicine, Adjuvant therapy, Medicine, Humans, Neoplasm Invasiveness, rectal cancer, extramural venous invasion, Aged, Netherlands, Gynecology, Aged, 80 and over, Hereditary cancer and cancer-related syndromes [ONCOL 1], integumentary system, business.industry, Rectal Neoplasms, Incidence (epidemiology), Incidence, fungi, Case-control study, food and beverages, General Medicine, Middle Aged, medicine.disease, Prognosis, Combined Modality Therapy, Logistic Models, Oncology, Case-Control Studies, histopathology, Surgery, Histopathology, Female, Neoplasm Recurrence, Local, local recurrence, business
Abstract

Contains fulltext : 79958.pdf (Publisher’s version ) (Closed access) AIM: The main cause of local recurrence (LR) in rectal cancer is involvement of the circumferential resection margin (CRM). However, patients with a negative CRM can also develop LR, suggesting that additional factors are important for LR. The aim of this study was to identify histopathological factors predictive for the development of LR after primary rectal cancer treatment. METHODS: T x N x M0 patients treated for locally recurrent rectal cancer at the Catharina hospital from 1994 to 2006 (n=92) were matched with a control group of patients who did not develop LR after primary rectal cancer treatment for at least 2 years (n=185) based on the type of neoadjuvant treatment in a 1:2 ratio. The pathology of all primary rectal cancers was reviewed. Patient, treatment and histopathological characteristics were studied in relation to the development of LR with logistic regression. RESULTS: Logistic regression indicated the presence of lymphovascular invasion (LVI, OR 4.66, P

Published
2009

19. Noninvasive Characterisation of Short-and Long-Term Recurrence of Atrial Signals During Persistent Atrial Fibrillation

Author

Olivier Meste, Harry J.G.M. Crijns, Theo Lankveld, Muhammad Haziq Kamarul Azman, Ulrich Schotten, Joël Karel, Stef Zeemering, Pietro Bonizzi, Ralf Peeters, Department of data science and Knowledge Engineering [Maastricht], Maastricht University [Maastricht], Department of Physiology [Maastricht], Laboratoire d'Informatique, Signaux, et Systèmes de Sophia-Antipolis (I3S) / Equipe SIGNAL, Signal, Images et Systèmes (Laboratoire I3S - SIS), Laboratoire d'Informatique, Signaux, et Systèmes de Sophia Antipolis (I3S), Université Nice Sophia Antipolis (... - 2019) (UNS), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Centre National de la Recherche Scientifique (CNRS)-Université Côte d'Azur (UCA)-Université Nice Sophia Antipolis (... - 2019) (UNS), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Centre National de la Recherche Scientifique (CNRS)-Université Côte d'Azur (UCA)-Laboratoire d'Informatique, Signaux, et Systèmes de Sophia Antipolis (I3S), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Centre National de la Recherche Scientifique (CNRS)-Université Côte d'Azur (UCA), Department of Cardiology, Cardiovascular Research Institute Maastricht, Department of Physiology, Maastricht University, Department of Physiology, Maastricht University [Maastricht]-Maastricht University [Maastricht], DKE Scientific staff, RS: FSE DACS BMI, Fysiologie, RS: CARIM - R2.11 - Experimental atrial fibrillation, Cardiologie, MUMC+: MA Cardiologie (9), RS: CARIM - R2.01 - Clinical atrial fibrillation, and RS: FSE MaCSBio

Subjects
Therapy Outcome, medicine.medical_specialty, business.industry, 0206 medical engineering, 020206 networking & telecommunications, Atrial fibrillation, 02 engineering and technology, Mutually exclusive events, medicine.disease, 020601 biomedical engineering, Term (time), Internal medicine, Persistent atrial fibrillation, 0202 electrical engineering, electronic engineering, information engineering, medicine, Cardiology, [SDV.IB]Life Sciences [q-bio]/Bioengineering, business, [SPI.SIGNAL]Engineering Sciences [physics]/Signal and Image processing
Abstract

International audience; Propagation of electrical atrial activity (AA) during atrial fibrillation (AF) is a process characterized by different short-and long-term recurrence behaviours. Two anti-thetical (not mutually exclusive) hypotheses are proposed to noninvasively describe this nonstationary behaviour. The first hypothesis (H1) assumes a process with stationary spatial properties of AA propagation, but time-varying frequency properties, and vice versa for the second (H2). Based on H1 and H2, two phenomenological models were proposed, both able to replicate observations on AF patients, and a novel measure was introduced to assess the spatial variability of AA propagation (SVAAP) over short and long AA segments. Validity of the models was tested by looking at the relation between SVAAP-long and SVAAP-short on real observations from AF patients (high-density body surface potential maps recorded in 75 patients affected by persistent AF). H1 is confirmed if SVAAP-short is approximately equal to SVAAP-long. H2 if SVAAP-short is less than SVAAP-long. Results confirmed H2, showing that AA propagation during AF has strong nonstationary spatial properties. This could suggest new parameters to characterise AF sub-strate and predict therapy outcome.

20. Noninvasive recurrence quantification analysis predicts atrial fibrillation recurrence in persistent patients undergoing electrical cardioversion

Author

Olivier Meste, Theo Lankveld, Ulrich Schotten, Harry J.G.M. Crijns, Pietro Bonizzi, Joël Karel, Ralf Peeters, Stef Zeemering, Fysiologie, DKE Scientific staff, RS: FSE DACS BMI, Promovendi CD, Cardiologie, RS: CARIM - R2.11 - Experimental atrial fibrillation, MUMC+: MA Cardiologie (9), RS: CARIM - R2.01 - Clinical atrial fibrillation, RS: FSE MaCSBio, Meste, Olivier, Laboratoire d'Informatique, Signaux, et Systèmes de Sophia-Antipolis (I3S) / Equipe SIGNAL, Signal, Images et Systèmes (Laboratoire I3S - SIS), Laboratoire d'Informatique, Signaux, et Systèmes de Sophia Antipolis (I3S), Université Nice Sophia Antipolis (... - 2019) (UNS), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Centre National de la Recherche Scientifique (CNRS)-Université Côte d'Azur (UCA)-Université Nice Sophia Antipolis (... - 2019) (UNS), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Centre National de la Recherche Scientifique (CNRS)-Université Côte d'Azur (UCA)-Laboratoire d'Informatique, Signaux, et Systèmes de Sophia Antipolis (I3S), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Centre National de la Recherche Scientifique (CNRS)-Université Côte d'Azur (UCA), Department of Physiology, Maastricht University, Department of Physiology, Maastricht University [Maastricht]-Maastricht University [Maastricht], Department of data science and Knowledge Engineering [Maastricht], and Maastricht University [Maastricht]

Subjects
[SDV.IB] Life Sciences [q-bio]/Bioengineering, medicine.medical_specialty, COMPLEXITY, business.industry, 020206 networking & telecommunications, Atrial fibrillation, 02 engineering and technology, 030204 cardiovascular system & hematology, medicine.disease, Electrical cardioversion, 03 medical and health sciences, 0302 clinical medicine, Recurrence quantification analysis, Internal medicine, 0202 electrical engineering, electronic engineering, information engineering, medicine, Cardiology, [SDV.IB]Life Sciences [q-bio]/Bioengineering, In patient, Temporal organization, business, [SPI.SIGNAL]Engineering Sciences [physics]/Signal and Image processing, [SPI.SIGNAL] Engineering Sciences [physics]/Signal and Image processing
Abstract

International audience; This study proposes a novel noninvasive ECG-based approach to accurately quantify differences in the atrial activity (AA) signals of atrial fibrillation (AF) patients characterized by very similar global AF organization. High-density body surface potential maps were recorded in 63 patients in persistent AF prior to electrical car-dioversion (32 recurrences occurred after 4-6 weeks). AF substrate complexity was quantified as the degree of overall temporal organization of the AA pattern, determined from multi-variable unthresholded recurrence plots (RP). Results showed that non-recurrent patients were characterized by temporally more stable propagation patterns than recurrent patients, suggesting a lower complexity of the AF substrate in the former. This was used to discriminate between recurrent and non-recurrent AF patients following electrical cardioversion with an accuracy of 72%. Noninvasive assessment of AF substrate complexity in patients characterized by very similar levels of AF progression was improved by applying RP-based analysis on extracted AA signals. The proposed approach may help improving AF treatment selection and success.

Catalog

Books, media, physical & digital resources
See catalog results